Literature DB >> 24446693

Viral suppression in HIV studies: combining times to suppression and rebound.

Natalia A Gouskova1, Stephen R Cole, Joseph J Eron, Jason P Fine.   

Abstract

In HIV-1 clinical trials the interest is often to compare how well treatments suppress the HIV-1 RNA viral load. The current practice in statistical analysis of such trials is to define a single ad hoc composite event which combines information about both the viral load suppression and the subsequent viral rebound, and then analyze the data using standard univariate survival analysis techniques. The main weakness of this approach is that the results of the analysis can be easily influenced by minor details in the definition of the composite event. We propose a straightforward alternative endpoint based on the probability of being suppressed over time, and suggest that treatment differences be summarized using the restricted mean time a patient spends in the state of viral suppression. A nonparametric analysis is based on methods for multiple endpoint studies. We demonstrate the utility of our analytic strategy using a recent therapeutic trial, in which the protocol specified a primary analysis using a composite endpoint approach.
© 2014, The International Biometric Society.

Entities:  

Keywords:  AIDS; Clinical trial endpoint; Counting processes; Multistate models; Survival analysis

Mesh:

Substances:

Year:  2014        PMID: 24446693      PMCID: PMC4319678          DOI: 10.1111/biom.12140

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  13 in total

1.  Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.

Authors:  P B Gilbert; H J Ribaudo; L Greenberg; G Yu; R J Bosch; C Tierney; D R Kuritzkes
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

2.  A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

Authors:  Margaret A Fischl; Heather J Ribaudo; Ann C Collier; Alejo Erice; Marina Giuliano; Marjorie Dehlinger; Joseph J Eron; Michael S Saag; Scott M Hammer; Stefano Vella; Gene D Morse; Judith E Feinberg; Lisa M Demeter; Susan H Eshleman
Journal:  J Infect Dis       Date:  2003-08-15       Impact factor: 5.226

Review 3.  Trial design in the era of highly effective antiviral drug combinations for HIV infection.

Authors:  V DeGruttola; M Hughes; P Gilbert; A Phillips
Journal:  AIDS       Date:  1998       Impact factor: 4.177

4.  Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.

Authors:  M S Pepe; T R Fleming
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

5.  Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Christina Lalama; Bruce R Schackman; William A Meyer; Edward P Acosta; Jeffrey Schouten; Kathleen E Squires; Christopher D Pilcher; Robert L Murphy; Susan L Koletar; Margrit Carlson; Richard C Reichman; Barbara Bastow; Karin L Klingman; Daniel R Kuritzkes
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

6.  Design issues in initial HIV-treatment trials: focus on ACTG A5095.

Authors:  Heather J Ribaudo; Daniel R Kuritzkes; Bruce R Schackman; Edward P Acosta; Cecilia M Shikuma; Roy M Gulick
Journal:  Antivir Ther       Date:  2006

7.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar
Journal:  N Engl J Med       Date:  2009-12-01       Impact factor: 91.245

9.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

10.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

View more
  7 in total

1.  Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies.

Authors:  Bo Huang; Lu Tian; Zachary R McCaw; Xiaodong Luo; Enayet Talukder; Mace Rothenberg; Wanling Xie; Toni K Choueiri; Dae Hyun Kim; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

2.  Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy.

Authors:  Jessie K Edwards; Stephen R Cole; Adaora Adimora; Jason Fine; Jeff Martin; Joseph Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2015-02-01       Impact factor: 3.731

3.  Longitudinal HIV care outcomes by gender identity in the United States.

Authors:  Catherine R Lesko; Jessie K Edwards; David B Hanna; Angel M Mayor; Michael J Silverberg; Michael Horberg; Peter F Rebeiro; Richard D Moore; Ashleigh J Rich; Kathleen A McGinnis; Kate Buchacz; Heidi M Crane; Charles S Rabkin; Keri N Althoff; Tonia C Poteat
Journal:  AIDS       Date:  2022-07-21       Impact factor: 4.632

4.  A Two-stage Approach for Rapid Assessment of the Proportion Achieving Viral Suppression Using Routine Clinical Data.

Authors:  Jessie K Edwards; Yeycy Donastorg; Sabrina Zadrozny; Sarah Hileman; Hoisex Gómez; Marissa J Seamans; Michael E Herce; Edwin Ramírez; Clare Barrington; Sharon Weir
Journal:  Epidemiology       Date:  2022-05-30       Impact factor: 4.860

5.  Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens.

Authors:  Jessie K Edwards; Stephen R Cole; H Irene Hall; W Christopher Mathews; Richard D Moore; Michael J Mugavero; Joseph J Eron
Journal:  AIDS       Date:  2018-01-14       Impact factor: 4.177

6.  One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States.

Authors:  Fidel A Desir; Catherine R Lesko; Richard D Moore; Michael A Horberg; Cherise Wong; Heidi M Crane; Michael Silverberg; Jennifer E Thorne; Beth Rachlis; Charles Rabkin; Angel M Mayor; William C Mathews; Keri N Althoff
Journal:  Clin Infect Dis       Date:  2019-02-15       Impact factor: 9.079

7.  A longitudinal, HIV care continuum: 10-year restricted mean time in each care continuum stage after enrollment in care, by history of IDU.

Authors:  Catherine R Lesko; Jessie K Edwards; Richard D Moore; Bryan Lau
Journal:  AIDS       Date:  2016-09-10       Impact factor: 4.177

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.